Literature DB >> 21779439

From Hen House to Bedside: Tracing Hanafusa's Legacy from Avian Leukemia Viruses to SRC to ABL and Beyond.

Michael G Kharas1, George Q Daley.   

Abstract

The discovery of the Src oncogene was the first step on a long journey toward improved cancer chemotherapy. In this review, we explore Src and BCR-ABL, signal transduction, and recent advances in oncogene addiction and celebrate Hidesaboro Hanafusa and the many researchers who ushered in the age of target-directed therapy against tyrosine kinase oncoproteins.

Entities:  

Keywords:  Abl; Hanafusa; Src

Year:  2010        PMID： 21779439      PMCID： PMC3092284          DOI： 10.1177/1947601911407327

Source DB:  PubMed          Journal:  Genes Cancer        ISSN： 1947-6019


  108 in total

1.  Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRalpha, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants.

Authors:  Ellen Weisberg; Hwan Geun Choi; Arghya Ray; Rosemary Barrett; Jianming Zhang; Taebo Sim; Wenjun Zhou; Markus Seeliger; Michael Cameron; Mohammed Azam; Jonathan A Fletcher; Maria Debiec-Rychter; Mark Mayeda; Daisy Moreno; Andrew L Kung; Pasi Antero Janne; Roya Khosravi-Far; Junia V Melo; Paul W Manley; Sophia Adamia; Catherine Wu; Nathanael Gray; James D Griffin
Journal:  Blood       Date:  2010-03-18       Impact factor: 22.113

2.  Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome.

Authors:  G Q Daley; R A Van Etten; D Baltimore
Journal:  Science       Date:  1990-02-16       Impact factor: 47.728

3.  Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.

Authors:  S Danhauser-Riedl; M Warmuth; B J Druker; B Emmerich; M Hallek
Journal:  Cancer Res       Date:  1996-08-01       Impact factor: 12.701

Review 4.  Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.

Authors:  Erica L Mayer; Ian E Krop
Journal:  Clin Cancer Res       Date:  2010-07-15       Impact factor: 12.531

5.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Authors:  Charles D Blanke; Cathryn Rankin; George D Demetri; Christopher W Ryan; Margaret von Mehren; Robert S Benjamin; A Kevin Raymond; Vivien H C Bramwell; Laurence H Baker; Robert G Maki; Michael Tanaka; J Randolph Hecht; Michael C Heinrich; Christopher D M Fletcher; John J Crowley; Ernest C Borden
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

6.  BCR/ABL P210 and P190 cause distinct leukemia in transgenic mice.

Authors:  J W Voncken; V Kaartinen; P K Pattengale; W T Germeraad; J Groffen; N Heisterkamp
Journal:  Blood       Date:  1995-12-15       Impact factor: 22.113

7.  BCR/ABL P190 transgenic mice develop leukemia in the absence of Crkl.

Authors:  Bianca Hemmeryckx; Anja Reichert; Meguru Watanabe; Vesa Kaartinen; Ron de Jong; Paul K Pattengale; John Groffen; Nora Heisterkamp
Journal:  Oncogene       Date:  2002-05-09       Impact factor: 9.867

8.  BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

Authors:  Nicholas J Donato; Ji Yuan Wu; Jonathan Stapley; Gary Gallick; Hui Lin; Ralph Arlinghaus; Moshe Talpaz
Journal:  Blood       Date:  2003-01-15       Impact factor: 22.113

9.  Recovery of avian sarcoma virus from tumors induced by transformation-defective mutants.

Authors:  H Hanafusa; C C Halpern; D L Buchhagen; S Kawai
Journal:  J Exp Med       Date:  1977-12-01       Impact factor: 14.307

10.  The COOH terminus of the c-Abl tyrosine kinase contains distinct F- and G-actin binding domains with bundling activity.

Authors:  R A Van Etten; P K Jackson; D Baltimore; M C Sanders; P T Matsudaira; P A Janmey
Journal:  J Cell Biol       Date:  1994-02       Impact factor: 10.539
View more
  3 in total

1.  C-Src and c-Yes are two unlikely partners of spermatogenesis and their roles in blood-testis barrier dynamics.

Authors:  Xiang Xiao; Dolores D Mruk; Faith L Cheng; C Yan Cheng
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 2.  Cancer prevention as biomodulation: targeting the initiating stimulus and secondary adaptations.

Authors:  Priscilla A Furth
Journal:  Ann N Y Acad Sci       Date:  2012-10       Impact factor: 5.691

3.  Lyn facilitates glioblastoma cell survival under conditions of nutrient deprivation by promoting autophagy.

Authors:  Wei Michael Liu; Ping Huang; Niladri Kar; Monica Burgett; Gaelle Muller-Greven; Amy S Nowacki; Clark W Distelhorst; Justin D Lathia; Jeremy N Rich; John C Kappes; Candece L Gladson
Journal:  PLoS One       Date:  2013-08-02       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.